Back to top

Tandem Diabetes price target raised to $24 from $21 at Citi

Citi analyst Joanne Wuensch raised the firm’s price target on Tandem Diabetes (TNDM) to $24 from $21 and keeps a Neutral rating on the shares. The ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Tandem Diabetes Care, Inc. (TNDM)